So they added Braden P. Rae to the Cytodyn webpage
Post# of 153887
(Total Views: 744)
Posted On: 02/08/2022 4:09:21 PM
So they added Braden P. Rae to the Cytodyn webpage. Why did they wait to add him, he joined us back in November. Maybe they haven’t gotten around to updating the site and that’s why.
“Brendan P. Rae, Ph.D., J.D.
Senior Vice President of Business Development
Dr. Rae rejoined CytoDyn in November 2021 from Qilu Pharmaceutical Co., Ltd. He brings a wealth of experience in business development and licensing to the company from both pharma and biotech. Dr. Rae started his licensing and business development career at Roche and has a proven track record of success in the biotech industry during his tenure at VIA Pharmaceuticals, Arrowhead and NPS which was acquired by Shire in 2015 for $5.4 B. He has led negotiations and closed transactions in the US, Europe and Japan and has experience working in the Chinese pharmaceutical market. Prior to the biopharmaceutical industry, Dr. Rae was an attorney specializing in biopharmaceutical intellectual property law and, earlier in his career was a research scientist focusing on metastasis and the molecular basis of cellular transformation. Dr. Rae holds a Juris Doctor degree from Seton Hall Law School and a Ph.D. in Virology from Glasgow University (Scotland) and completed a Postdoctoral Fellowship at the Roche Institute of Molecular Biology.”
“Brendan P. Rae, Ph.D., J.D.
Senior Vice President of Business Development
Dr. Rae rejoined CytoDyn in November 2021 from Qilu Pharmaceutical Co., Ltd. He brings a wealth of experience in business development and licensing to the company from both pharma and biotech. Dr. Rae started his licensing and business development career at Roche and has a proven track record of success in the biotech industry during his tenure at VIA Pharmaceuticals, Arrowhead and NPS which was acquired by Shire in 2015 for $5.4 B. He has led negotiations and closed transactions in the US, Europe and Japan and has experience working in the Chinese pharmaceutical market. Prior to the biopharmaceutical industry, Dr. Rae was an attorney specializing in biopharmaceutical intellectual property law and, earlier in his career was a research scientist focusing on metastasis and the molecular basis of cellular transformation. Dr. Rae holds a Juris Doctor degree from Seton Hall Law School and a Ph.D. in Virology from Glasgow University (Scotland) and completed a Postdoctoral Fellowship at the Roche Institute of Molecular Biology.”
(8)
(0)